Primary Care Diabetes
Volume 4 , Pages S24-S30 , April 2010

Diabetes and weight management

  • David C.W. Lau

      Affiliations

    • Corresponding Author InformationCorrespondence: David CW Lau, MD, PhD, FRCPC. Professor of Medicine, Biochemistry and Molecular Biology, Chair, Diabetes and Endocrine Research Group, Julia McFarlane Diabetes Research Centre, University of Calgary, Calgary, Alberta, Canada. Tel: +1 403 220 2261; fax: +1 403 210 8113

References 

  1. Hossain P , Kawar B , El Nahas M . Obesity and diabetes in the developing world – a growing challenge . N. Engl. J Med. . 2007;356:213–215
  2. International Diabetes Federation  . Diabetes Atlas . www.eatlas.idf.org (accessed 6 July 2009).
  3. World Health Organization  . Facts about diabetes . http://www.who.int/features/factfiles/diabetes/04_en.html
  4. Colditz GA , Willett WC , Rotnitzky A , Manson JE . Weight gain as a risk factor for clinical diabetes mellitus in women . Ann. Intern. Med. . 1995;122:481–486
  5. Carey VJ , Walters EE , Colditz GA , et al.   Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study . Am. J Epidemiol. . 1997;145:614–619
  6. Chan JM , Rimm EB , Colditz GA , et al.   Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men . Diabetes Care . 1994;17:961–969
  7. World Health Organization  . Facts about obesity and overweight . http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/
  8. Prospective Studies Collaboration Whitlock G , Lewington S , et al.   Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies . Lancet . 2009;373:1083–1096
  9. Anderson JW , Konz EC . Obesity and disease management: effects of weight loss on comorbid conditions . Obes. Res. . 2001;9(Suppl. 4):S326–S334
  10. Yusuf S , Hawken S , Ôunpuu S , et al.   Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study . Lancet . 2004;364:937–952
  11. Oldridge NB , Stump TE , Nothwehr FK , Clark DO . Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle-and older-age adults . J. Clin. Epidemiol. . 2001;54:928–934
  12. The Diabetes Control and Complications Trial Research Group  . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus . N. Engl. J Med. . 1993;329:977–986
  13. Holman RR , Paul SK , Bethel MA , et al.   10-year follow-up of intensive glucose control in type 2 diabetes . N. Engl. J Med. . 2008;359:1577–1589
  14. Wing RR , Marcus MD , Epstein LH , Salata R . Type II diabetic subjects lose less weight than their overweight nondiabetic spouses . Diabetes Care . 1987;10:563–566
  15. Anderson JW , Kendall CW , Jenkins DJ . Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies . J. Am. Coll. Nutr. . 2003;22:331–339
  16. Diabetes Prevention Program Research Group  . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N. Engl. J Med. . 2002;346:393–403
  17. Tuomilehto J , Lindstrom J , Eriksson JG , et al.   Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance . N. Engl. J Med. . 2001;344:1343–1350
  18. Knowler WC , Fowler SE , Hamman RF , et al.   10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study . Lancet . 2009;374:1677–1686
  19. Lindström J , Ilanne-Parikka P , Peltonen M , et al.   Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study . Lancet . 2006;368:1673–1679
  20. Williamson DF , Thompson TJ , Thun M , et al.   Intentional weight loss and mortality among overweight individuals with diabetes . Diabetes Care . 2000;23:1499–1504
  21. Lean ME , Powrie JK , Anderson AS , Garthwaite PH . Obesity, weight loss and prognosis in type 2 diabetes . Diabet. Med. . 1990;7:228–233
  22. Khan MA , St Peter JV , Breen GA , et al.   Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants . Obes. Res. . 2000;8:43–48
  23. Hensrud DD . Dietary treatment and long-term weight loss and maintenance in type 2 diabetes . Obes. Res. . 2001;9(Suppl. 4):S348–S353
  24. Guare JC , Wing RR , Grant A . Comparison of obese NIDDM and nondiabetic women: short-and long-term weight loss . Obes. Res. . 1995;3:329–335
  25. Lau DCW . Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children . CMAJ . 2007;176:1103–1106
  26. UK Prospective Diabetes Study (UKPDS) Group  . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) . Lancet . 1998;352:837–853
  27. Turner RC , Cull CA , Frighi V , Holman RR . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group . JAMA . 1999;281:2005–2012
  28. Russell-Jones D , Khan R . Insulin-associated weight gain in diabetes – causes, effects and coping strategies . Diabetes Obes. Metab. . 2007;9:799–812
  29. Mitri J , Hamdy O . Diabetes medications and body weight . Expert Opin. Drug Saf. . 2009;8:573–584
  30. Nathan DM , Buse JB , Davidson MB , et al.   Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes . Diabetologia . 2009;52:17–30
  31. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee  . Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada . Can. J Diabetes . 2008;32(Suppl. 1):S53–S61
  32. Peyrot M , Rubin RR , Lauritzen T , et al.   Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study . Diabetes Care . 2005;28:2673–2679
  33. Kurtzhals P . How to achieve a predictable basal insulin? . Diabetes Metab. . 2005;31:4S25; 4S33
  34. Klein O , Lynge J , Endahl L , et al.   Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes . Diabetes Obes. Metab. . 2007;9:290–299
  35. Hollander P , Cooper J , Bregnhøj J , Pedersen CB . A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes . Clin. Ther. . 2008;30:1976–1987
  36. Rosenstock J , Davies M , Home PD , et al.   A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes . Diabetologia . 2008;51:408–416
  37. Fajardo Montañana C , Hernández Herrero C , Rivas Fernández M . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial . Diabet. Med. . 2008;25:916–923
  38. Haak T , Tiengo A , Draeger E , et al.   Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes . Diabetes Obes. Metab. . 2005;7:56–64
  39. Hermansen K , Davies M , Derezinski T , et al.   A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes . Diabetes Care . 2006;29:1269–1274
  40. Philis-Tsimikas A , Charpentier G , Clauson P , et al.   Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes . Clin. Ther. . 2006;28:1569–1581
  41. Rašlová K , Bogoev M , Raz I , et al.   Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes . Diabetes Res. Clin. Pract. . 2004;66:193–201
  42. Monami M , Marchionni N , Mannucci E . Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis . Diabetes Res. Clin. Pract. . 2008;81:184–189
  43. Philis-Tsimikas A . Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes . Patient Prefer. Adherence . 2008;2:323–332
  44. Lüddeke HJ , Sreenan S , Aczel S , et al.   PREDICTIVE – a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort . Diabetes Obes. Metab. . 2007;9:428–434
  45. Dornhorst A , Lüddeke HJ , Sreenan S , et al.   Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE™ study . Int. J Clin. Pract. . 2008;62:659–665
  46. Hordern SVM , Wright JE , Umpleby AM , et al.   Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp . Diabetologia . 2005;48:420–426

PII: S1751-9918(10)60006-X

doi: 10.1016/S1751-9918(10)60006-X

Primary Care Diabetes
Volume 4 , Pages S24-S30 , April 2010

Article Tools